[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592830":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":23,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Izmir City Hospital","OTHER_GOV",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Group 1: α-1 adrenergic blocker users",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Group 2: No α-1 adrenergic blockers.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Tuba Kuvvet Yoldas, MD","CONTACT","+905053428504","tubayoldas2297@gmail.com",{"name":20,"role":16,"phone":21,"phoneExt":10,"email":22},"Mehmet Yoldas, MD","+905304646231","yoldas_2297@gmail.com",[24],{"facility":25,"status":10,"city":26,"state":27,"zip":28,"country":29,"countryCode":10,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"İzmir City Hospital","Izmir","Bayraklı","35000","Turkey (Türkiye)",{"type":31,"coordinates":32},"Point",[33,34],27.13838,38.41273,{"lat":34,"lon":33},[37,41,43,45,47],{"name":38,"role":16,"phone":39,"phoneExt":10,"email":40},"İzmir City Hospital İzmir City Hospital","+902329550500","izmirsh@saglik.gov.tr",{"name":15,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":20,"role":44,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":46,"role":44,"phone":10,"phoneExt":10,"email":10},"Aylin Ateşalp, MD",{"name":48,"role":44,"phone":10,"phoneExt":10,"email":10},"Nevin Esra Gümüş, MD",{"type":42,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Tuba Kuvvet Yoldaş","MD,Specialist","100592830","hemodynamic-effects-of-alpha-blockers-in-patients-with-spinal-anesthesia-100592830",false,"NCT06998537","Hemodynamic Effects of Alpha Blockers in Patients With Spinal Anesthesia","The Effect of Spinal Anaesthesia on Haemodynamic Parameters in Patients Receiving Alpha Blockers","Inclusion Criteria:\n\n* Patients with American Society of Anesthesiologists (ASA) physical status classification I,II or III over 18 years of age scheduled for elective urologic surgery under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients not undergoing spinal anesthesia, non-alpha-blocker vasoactive drug users, patients with cardiac disease, medical\u002Fsurgical history of brain or spinal cord, neurological or psychiatric disease","ALL","18 Years",{"count":62,"type":63},80,"ESTIMATED","OBSERVATIONAL","There is frequent use of alpha blockers in elderly patients with urological disorders. Various side effects are encountered due to the use of alpha blockers in the elderly age group. Especially hypotension is one of the common side effects. In addition, urological surgery is frequently performed in this age group. Spinal anesthesia is the most preferred anesthesia method in urological surgery. Spinal anesthesia may cause significant vasodilatation and thus hemodynamic changes such as hypotension by causing sympathetic nerve blockade. It is predicted that spinal anesthesia may increase these effects especially in individuals using α-1 adrenergic blockers. In the literature, serious hypotension has been encountered in individuals using alpha blockers under general anesthesia. The aim of this study was to compare the intraoperative hemodynamic changes in patients undergoing elective urologic surgery under spinal anesthesia between α-1 adrenergic blocker users (Group 1) and non-users(Group 2). Patients were divided into two groups according to drug use: Group 1: α-1 adrenergic blocker users (alfuzosin, doxazosin, terazosin,silodosin, tamsulosin), Group 2: No α-1 adrenergic blockers.",[67],"Patient Group With Alpha Blocker Use",[69,70,71],"spinal anesthesia","adrenergic α1-receptor antagonists,","Urologic Surgical Procedures","NOT_YET_RECRUITING","2025-08-19",{"date":75,"type":76},"2025-08-20","ACTUAL",{"date":78,"type":63},"2025-08-30",{"date":80,"type":63},"2025-10-30",{"name":5,"class":6},1]